Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times ...

MoonLake’s stock rocketed 20% after reports claimed Merck made a $3 billion acquisition offer to boost its drug pipeline.

Stocks closed higher on Tuesday as the Nasdaq Composite finished the day higher for the year even as uncertainty over global ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

North Branch Land Trust is inviting nature lovers, conservationists and families to attend their Paddle and Pour event at 11 ...

Duck Dynasty's' Phil Robertson, who is suffering with Alzheimer's disease, harvested his first ducks as an 11-year-old boy ...

MoonLake Immunotherapeutics (NASDAQ:MLTX), a biopharmaceutical company focused on developing treatments for various diseases, finds itself at a crucial juncture in its growth trajectory. With a clear ...

MoonLake Immunotherapeutics (NASDAQ:MLTX), a biopharmaceutical company focused on developing treatments for various diseases, finds itself at a crucial juncture in its growth trajectory.

Needham & Company LLC reiterated their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research note released on Wednesday morning,Benzinga reports.